{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:46:27Z","timestamp":1792701987585,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s40265-023-01992-4","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T02:02:35Z","timestamp":1708653755000},"page":"227-238","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Tirzepatide: A Review in Type 2 Diabetes"],"prefix":"10.1007","volume":"84","author":[{"given":"Nicole L.","family":"France","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahiya Y.","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"1992_CR1","unstructured":"Goyal RJI. Type 2 diabetes. [updated 2023 June 23] In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Jan. 2023. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30020625. Accessed 19 Dec 2023."},{"issue":"11","key":"1992_CR2","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753\u201386.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"1992_CR3","doi-asserted-by":"publisher","first-page":"S140","DOI":"10.2337\/dc23-S009","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S140\u2013S157.","journal-title":"Diabetes Care"},{"issue":"1","key":"1992_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s13300-020-00981-0","volume":"12","author":"T Min","year":"2021","unstructured":"Min T, Bain SC. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials. Diabetes Ther. 2021;12(1):143\u201357.","journal-title":"Diabetes Ther"},{"issue":"Suppl 1","key":"1992_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.13129","volume":"20","author":"MA Nauck","year":"2018","unstructured":"Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(Suppl 1):5\u201321.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1992_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.14831","volume":"25","author":"C De Block","year":"2023","unstructured":"De Block C, Bailey C, Wysham C, et al. Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective. Diabetes Obes Metab. 2023;25(1):3\u201317.","journal-title":"Diabetes Obes Metab"},{"key":"1992_CR7","unstructured":"European Medicines Agency. Mounjaro (tirzepatide): summary of product characteristics 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mounjaro. Accessed 19 Dec 2023."},{"key":"1992_CR8","unstructured":"Eli Lilly and Company. Mounjaro\u2014tirzepatide injection, solution: US prescribing information. 2023. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0. Accessed 19 Dec 2023."},{"issue":"9","key":"1992_CR9","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S2213-8587(22)00188-7","volume":"10","author":"N Inagaki","year":"2022","unstructured":"Inagaki N, Takeuchi M, Oura T, et al. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(9):623\u201333.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1992_CR10","unstructured":"Therapeutic Goods Administration. Australian prescription medicine decision summaries: Mounjaro. 2023. https:\/\/www.tga.gov.au\/resources\/auspmd\/mounjaro. Accessed 19 Dec 2023."},{"key":"1992_CR11","unstructured":"National Institute for Health and Care Excellence (NICE). Tirzepatide for treating type 2 diabetes. 2023. https:\/\/www.nice.org.uk\/guidance\/ta924\/resources\/tirzepatide-fo-treating-type-2-diabetess-pdf-82615547603653. Accessed 19 Dec 2023."},{"key":"1992_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","volume":"18","author":"T Coskun","year":"2018","unstructured":"Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3\u201314.","journal-title":"Mol Metab"},{"issue":"13","key":"1992_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1073\/pnas.2116506119","volume":"119","author":"B Sun","year":"2022","unstructured":"Sun B, Willard FS, Feng D, et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proc Natl Acad Sci U S A. 2022;119(13):1\u201311.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1992_CR14","doi-asserted-by":"crossref","unstructured":"Samms RJ, Christe ME, Collins KA, et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. J Clin Invest. 2021;131(12).","DOI":"10.1172\/JCI146353"},{"issue":"6","key":"1992_CR15","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S2213-8587(22)00085-7","volume":"10","author":"T Heise","year":"2022","unstructured":"Heise T, Mari A, DeVries JH, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol. 2022;10(6):418\u201329.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"1992_CR16","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","volume":"106","author":"MK Thomas","year":"2021","unstructured":"Thomas MK, Nikooienejad A, Bray R, et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab. 2021;106(2):388\u201396.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1992_CR17","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1111\/dom.15140","volume":"25","author":"SD Pedersen","year":"2023","unstructured":"Pedersen SD, Giorgino F, Umpierrez G, et al. Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: a post hoc assessment of the SURPASS clinical trial programme. Diabetes Obes Metab. 2023;25(9):2553\u201360.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1992_CR18","doi-asserted-by":"publisher","first-page":"bvad056","DOI":"10.1210\/jendso\/bvad056","volume":"7","author":"CJ Lee","year":"2023","unstructured":"Lee CJ, Mao H, Thieu VT, et al. Tirzepatide as monotherapy improved markers of beta-cell function and insulin sensitivity in type 2 diabetes (SURPASS-1). J Endocr Soc. 2023;7(5):bvad056.","journal-title":"J Endocr Soc"},{"issue":"1","key":"1992_CR19","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/dom.14553","volume":"24","author":"JM Wilson","year":"2022","unstructured":"Wilson JM, Lin Y, Luo MJ, et al. The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: a post hoc analysis. Diabetes Obes Metab. 2022;24(1):148\u201353.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"1992_CR20","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1111\/dom.14174","volume":"22","author":"JM Wilson","year":"2020","unstructured":"Wilson JM, Nikooienejad A, Robins DA, et al. The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes Obes Metab. 2020;22(12):2451\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"1992_CR21","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1210\/clinem\/dgab722","volume":"107","author":"V Pirro","year":"2022","unstructured":"Pirro V, Roth KD, Lin Y, et al. Effects of tirzepatide, a dual GIP and GLP-1 RA, on lipid and metabolite profiles in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2022;107(2):363\u201378.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"1992_CR22","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1111\/dom.14110","volume":"22","author":"S Urva","year":"2020","unstructured":"Urva S, Coskun T, Loghin C, et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obes Metab. 2020;22(10):1886\u201391.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"1992_CR23","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/dom.14572","volume":"24","author":"K Furihata","year":"2022","unstructured":"Furihata K, Mimura H, Urva S, et al. A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes. Diabetes Obes Metab. 2022;24(2):239\u201346.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"1992_CR24","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s40262-021-01012-2","volume":"60","author":"S Urva","year":"2021","unstructured":"Urva S, Quinlan T, Landry J, et al. Effects of renal impairment on the pharmacokinetics of the dual GIP and GLP-1 receptor agonist tirzepatide. Clin Pharmacokinet. 2021;60(8):1049\u201359.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"1992_CR25","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40262-022-01140-3","volume":"61","author":"S Urva","year":"2022","unstructured":"Urva S, Quinlan T, Landry J, et al. Effects of hepatic impairment on the pharmacokinetics of the dual GIP and GLP-1 receptor agonist tirzepatide. Clin Pharmacokinet. 2022;61(7):1057\u201367.","journal-title":"Clin Pharmacokinet"},{"issue":"10160","key":"1992_CR26","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","volume":"392","author":"JP Frias","year":"2018","unstructured":"Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392(10160):2180\u201393.","journal-title":"Lancet"},{"issue":"6","key":"1992_CR27","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/s41591-023-02344-1","volume":"29","author":"L Gao","year":"2023","unstructured":"Gao L, Lee BW, Chawla M, et al. Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-combo trial. Nat Med. 2023;29(6):1500\u201310.","journal-title":"Nat Med."},{"issue":"10300","key":"1992_CR28","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","volume":"398","author":"B Ludvik","year":"2021","unstructured":"Ludvik B, Giorgino F, J\u00f3dar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583\u201398.","journal-title":"Lancet"},{"issue":"10313","key":"1992_CR29","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","volume":"398","author":"S Del Prato","year":"2021","unstructured":"Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811\u201324.","journal-title":"Lancet"},{"issue":"9","key":"1992_CR30","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/S2213-8587(22)00187-5","volume":"10","author":"T Kadowaki","year":"2022","unstructured":"Kadowaki T, Chin R, Ozeki A, et al. Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(9):634\u201344.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"1992_CR31","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jama.2022.0078","volume":"327","author":"D Dahl","year":"2022","unstructured":"Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327(6):534\u201345.","journal-title":"JAMA"},{"issue":"10295","key":"1992_CR32","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143\u201355.","journal-title":"Lancet"},{"issue":"6","key":"1992_CR33","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503\u201315.","journal-title":"N Engl J Med"},{"issue":"17","key":"1992_CR34","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1001\/jama.2023.20294","volume":"330","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock J, Frias JP, Rodbard HW, et al. Tirzepatide vs insulin lispro added to basal insulin in type 2 diabetes: the SURPASS-6 randomized clinical trial. JAMA. 2023;330(17):1631\u201340.","journal-title":"JAMA"},{"issue":"6","key":"1992_CR35","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","volume":"10","author":"A Gastaldelli","year":"2022","unstructured":"Gastaldelli A, Cusi K, Fern\u00e1ndez Land\u00f3 L, et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10(6):393\u2013406.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1992_CR36","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s13300-023-01451-z","volume":"14","author":"KS Boye","year":"2023","unstructured":"Boye KS, Thieu VT, Sapin H, et al. Patient-reported outcomes in people with type 2 diabetes receiving tirzepatide in the SURPASS clinical trial programme. Diabetes Ther. 2023;14:1833\u201352.","journal-title":"Diabetes Ther"},{"key":"1992_CR37","doi-asserted-by":"crossref","unstructured":"Boye K, Sapin H, Poon JL, et al. Tirzepatide improves HRQoL compared with insulin lispro in poorly controlled basal insulin-treated adults with long-standing T2D (SURPASS-6) [abstract no. 753-P]. Diabetes. 2023;72(Suppl 1).","DOI":"10.2337\/db23-753-P"},{"issue":"3","key":"1992_CR38","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","volume":"28","author":"N Sattar","year":"2022","unstructured":"Sattar N, McGuire DK, Pavo I, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28(3):591\u20138.","journal-title":"Nat Med"},{"key":"1992_CR39","unstructured":"Center for Drug Evaluation and Research (CDER). Tirzepatide (Mounjaro) summary review. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/215866Orig1s000SumR.pdf. Accessed 19 Dec 2023."},{"issue":"2","key":"1992_CR40","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1210\/clinem\/dgad532","volume":"109","author":"GR Mullins","year":"2024","unstructured":"Mullins GR, Hodsdon ME, Li YG, et al. Tirzepatide immunogenicity on pharmacokinetics, efficacy, and safety: analysis of data from phase 3 studies. J Clin Endocrinol Metab. 2024;109(2):361\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"1992_CR41","unstructured":"National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management. 2015. https:\/\/www.nice.org.uk\/guidance\/ng28\/resources\/type-2-diabetes-in-adults-management-pdf-1837338615493. Accessed 19 Dec 2023."},{"key":"1992_CR42","unstructured":"International Diabetes Federation. IDF clinical practice recommendations for managing type 2 diabetes in primary care. 2017. https:\/\/idf.org\/media\/uploads\/2023\/05\/attachments-63.pdf. Accessed 19 Dec 2023."},{"issue":"8","key":"1992_CR43","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00125-022-05715-4","volume":"65","author":"T Karagiannis","year":"2022","unstructured":"Karagiannis T, Avgerinos I, Liakos A, et al. Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022;65(8):1251\u201361.","journal-title":"Diabetologia"},{"issue":"9","key":"1992_CR44","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1111\/dom.14775","volume":"24","author":"K Vadher","year":"2022","unstructured":"Vadher K, Patel H, Mody R, et al. Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: an adjusted indirect treatment comparison. Diabetes Obes Metab. 2022;24(9):1861\u20138.","journal-title":"Diabetes Obes Metab"},{"key":"1992_CR45","unstructured":"Karagiannis T, Avgerinos I, Malandris K, et al. Tirzepatide compared to subcutanous semaglutide for type 2 diabetes: a network meta-analysis [abstract plus presentation OP 01; 5]. In: 59th European Association for the Study of Diabetes Annual Meeting 2023."},{"key":"1992_CR46","unstructured":"European Medicines Agency. Trulicity (dulaglutide): summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/trulicity. Accessed 19 Dec 2023."},{"issue":"6","key":"1992_CR47","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/dom.13979","volume":"22","author":"JP Frias","year":"2020","unstructured":"Frias JP, Nauck MA, Van J, et al. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab. 2020;22(6):938\u201346.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1992_CR48","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1111\/dom.14988","volume":"25","author":"MA Nauck","year":"2023","unstructured":"Nauck MA, Mirna AEA, Quast DR. Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: an update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide\/GLP-1 receptor co-agonist tirzepatide. Diabetes Obes Metab. 2023;25(5):1361\u201371.","journal-title":"Diabetes Obes Metab"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01992-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01992-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01992-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T06:37:25Z","timestamp":1711780645000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01992-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1992"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01992-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"20 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"N. L. France and Y. Y. Syed are salaried employees of Adis International Ltd\/Springer Nature and declare no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}